Find a study
Browse recruiting studies near you — free to check, always your choice.
138 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- Kidney disease
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
Testing whether empagliflozin is safe and helps children with chronic kidney disease
📍 University of Alabama at Birmingham · Birmingham, AL · +29 more US sites · Get directions →
This study is open to children aged 2 to 17 with chronic kidney disease (CKD). The purpose of this study is to find out if a medicine called empagliflozin helps children and adolescents with CKD.
- Obesity / overweight
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
Testing a 52-week medicine versus placebo in adults with obstructive sleep apnea on CPAP
📍 Valley Clinical Trials · Northridge, CA · +12 more US sites · Get directions →
This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are receiving positive airway pressure (PAP) therapy and are living with overweight or obesity.
- Obesity / overweight
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
Testing whether obesity genes predict weight loss from a diet and a medicine
📍 Columbia University Medical Center · New York, NY · Get directions →
The goal of this clinical trial is to understand if genetic variations are associated with the amount of weight loss with diet and while taking an FDA-approved medication for weight loss. The main question\[s\] it aims to answer are: * In Aim One, the investigators propose to rigorously test the hypothesis that presence of the Taq1A A1+ polymorphism is associated with greater weight loss with NB compared with the A1- genotype.
- Heart / cardiovascular diseaseKidney disease
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Testing whether orforglipron changes heart outcomes in adults with heart disease and/or kidney
📍 Instituto de Investigaciones Clínicas Bahia Blanca · Bahía Blanca, · Get directions →
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
- Kidney disease
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
Comparing how two beta-blockers work in hemodialysis patients on heart outcomes
📍 VA Long Beach Healthcare System, Long Beach, CA · Long Beach, CA · +7 more US sites · Get directions →
The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.
- Obesity / overweight
Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance
Testing how added dietary fiber and metformin, alone or together, affect insulin resistance and
📍 University of Alberta · Edmonton, Alberta · Get directions →
This is a 12-month, single center, three-arm parallel design, double-blind, randomized clinical trial, to compare the effects of supplemental dietary fiber and metformin (MET) alone and in combination over 12 months on glucose metabolism (insulin resistance \[IR\]), inflammation and BMI in adolescents with obesity and IR, and to assess the relationship between therapeutic intervention(s) and changes in gut microbiome composition and function. Since MET and FIBER have been shown to reduce weight and increase insulin sensitivity through distinct but overlapping mechanisms of action, our central hypothesis is that the combination of FIBER + MET will have a synergistic effect and be more effective than FIBER or MET alone in improving metabolic function (IR) and reducing BMI and inflammation in adolescents with obesity, IR and family history (FM) of T2DM.
- Obesity / overweight
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
Testing a weekly injection in people with obesity and sleep apnea to lose weight and improve sleep
📍 Dignity Health, Mercy Gilbert · Gilbert, AZ · +19 more US sites · Get directions →
This study is being done to look at the efficacy and safety of NNC0487-0111 in participants with overweight or obesity, and obstructive sleep apnoea treated with positive airway pressure. There are 2 study treatments in this study taken as injections under the skin once a week.
- Kidney disease
Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD
Testing whether empagliflozin changes kidney filter injury proteins in African American Veterans
📍 Washington DC Veterans Affairs Medical Center (688) · Washington D.C., DC · Get directions →
Primary Objective:To study podocyte specific injury markers in African American Veterans with non-diabetic kidney disease(NDKD), on empagliflozin therapy. Primary Endpoint: Assess the effect of Empagliflozin on podocyte-specific proteins in exosomes isolated from subjects' urine, such as nephrin, podocalyxin and Wilms'Tumor (WT-1) protein.
- Dementia / Alzheimer's
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
Testing the safety and effects of two drugs for agitation in Alzheimer’s dementia
📍 Esperanza Clinical · Murrieta, CA · +8 more US sites · Get directions →
The goal of this clinical trial is to evaluate the safety and efficacy of EXV-802 and EXV-801 in treatment of agitation in participants with Alzheimer's Disease dementia.
- Obesity / overweight
Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery
Testing medicines plus lifestyle counseling to manage weight regain after bariatric surgery
📍 University of California Irvine Medical Center · Orange, CA · Get directions →
This is a randomized controlled trial employing a Sequential Multiple Assignment Randomized Trial (SMART) design to test whether pharmacotherapy, in conjunction with lifestyle counseling, can reverse weight regain after bariatric surgery.
- Obesity / overweight
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
Testing a weekly under-the-skin injection to see effects on weight and diabetes markers
📍 Kailera Clinical Site · Cullman, AL · +34 more US sites · Get directions →
The primary objective of this study is to demonstrate that KAI-9531 subcutaneous (SC) injection once weekly is superior to placebo on: * Percent change in body weight * Change in hemoglobin A1c (HbA1c)
- Obesity / overweight
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
Testing a weekly under-the-skin medicine to help adults with obesity lose weight
📍 South Broward Research LLC · Miramar, FL · +21 more US sites · Get directions →
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week.
- Obesity / overweightType 2 diabetes
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Testing different doses of a medicine for weight loss in people with obesity or overweight and type
📍 Lakeview Clinical Research · Guntersville, AL · +33 more US sites · Get directions →
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants with obesity or overweight and Type 2 diabetes mellitus (T2DM).
- Obesity / overweight
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
Testing whether setmelanotide improves weight loss, hunger, and life quality in children and adults
📍 University of Alabama · Birmingham, AL · +7 more US sites · Get directions →
This is a sub-study of Study RM-493-040 (NCT05774756). The goal of this sub-study is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with congenital Hypothalamic Obesity (cHO).
- Sickle cell disease
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
Testing rilzabrutinib for safety and effectiveness in sickle-cell disease
📍 University of Alabama at Birmingham- Site Number : 8400003 · Birmingham, AL · +15 more US sites · Get directions →
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-adaptive, group-sequential study (Part A), followed by an open-label LTE period (Part B) to investigate the efficacy, and safety of rilzabrutinib in participants with sickle-cell disease (SCD). Study details include: * Study duration: a 52-week double-blind period (Part A), followed by an open-label LTE period (Part B).
- Obesity / overweightType 2 diabetes
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
Testing a medicine to see its safety and weight-loss effects in adults with obesity or overweight
📍 CenExel Anaheim Clinical Trials · Anaheim, CA · +39 more US sites · Get directions →
The purpose of this clinical study is to learn about the safety and effects of the study medicine to help adults with obesity or overweight and type 2 diabetes lose weight. Being overweight or obese means carrying too much body weight.
- Obesity / overweight
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Testing safety and effectiveness of weight-loss medicines for kids with obesity
📍 Carey Chronis MD Pediatric, Infant and Adolescent Medicine · Ventura, CA · +15 more US sites · Get directions →
The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.
- Kidney disease💵 May compensate
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease
Testing kidney disease drug effects and safety in teens with early CKD
📍 Instituto de atención Integral de Enfermedades Renales del Estado de Aguascalientes · Aguascalientes, Aguascalientes · Get directions →
Chronic kidney disease (CKD) is highly prevalent in the state of Aguascalientes, Mexico, particularly among adolescents and young adults. Epidemiologic and histologic studies suggest that this burden is largely driven by reduced nephron endowment of prenatal origin, leading to compensatory glomerular hyperfiltration, adaptive podocytopathy, and persistent albuminuria at early stages of disease.
- Dementia / Alzheimer's
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Testing whether KarXT plus KarX-EC is safe and works for memory problems in Alzheimer’s disease
📍 Healthy Brain Clinic · Long Beach, CA · +27 more US sites · Get directions →
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
- Obesity / overweight
Effect of Lidocaine-Dexmedetomidine on Pain, Inflammation, and Oxidative Stress After Bariatric Surgery.
Testing if an IV medicine during bariatric surgery reduces pain and inflammation in adults with
📍 Hospital de Especialidades Centro Medico Nacional Siglo XXI · Mexico City, Mexico City · Get directions →
The goal of this randomized clinical trial is to find out whether giving an intravenous lidocaine + dexmedetomidine combination (LIDEX) during laparoscopic bariatric surgery can lower post-operative pain, inflammation, and oxidative stress in adults with obesity. The main questions it aims to answer are: * Pain control: Does LIDEX reduce pain 24 hours after surgery, as measured with the International Pain Outcomes Questionnaire (IPOQ)?
- Obesity / overweight
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Testing eloralintide in people with sleep apnea and obesity
📍 Cullman Clinical Trials · Cullman, AL · +22 more US sites · Get directions →
The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2.
- Obesity / overweightHigh blood pressure
Impact GLP-1 Agonists Following Bariatric
Testing whether GLP-1 medicines after bariatric surgery affect weight and blood sugar
📍 University of Missouri Hospital · Columbia, MO · Get directions →
Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the pancreas, control hunger, induce satiety and plays a role in the metabolic health of a person. GLP-1 receptor agonists (GLP1-RAs) have been shown to be effective in achieving weight loss in patients with type 2 diabetes while improving blood glucose control.
- Dementia / Alzheimer's
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Testing long-term safety and effectiveness of two medicines for agitation in Alzheimer’s dementia
📍 Local Institution - 2609 · Chandler, AZ · +39 more US sites · Get directions →
The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who completed the parent studies CN012-0023 or CN012-0024.
- Obesity / overweight
DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity
Comparing HIV treatment medicines to see how they affect weight in people with obesity
📍 Hospital de infectología, Centro Médico Nacional La Raza · Mexico City, · Get directions →
Background:Historically, HIV infection was associated with significant weight loss. However, weight gain is now commonly observed after initiating antiretroviral therapy (ART), particularly in individuals underweight at baseline.
- Kidney disease
Randomised Evaluation of Sodium Dialysate Levels on Vascular Events
Testing whether two dialysate salt levels affect heart events and death
📍 Royal Adelaide Hospital · Adelaide, · Get directions →
This global study will assess the effect of randomising dialysis sites to one of two default dialysate sodium concentrations in current practice, 140mmol/l and 137mmol/l, on major cardiovascular events and death in patients receiving maintenance haemodialysis.
- Obesity / overweight
Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors
Testing a weekly shot to see if it is practical and helps weight in some postmenopausal breast
📍 Weill Cornell Medicine · New York, NY · Get directions →
This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal females with a history of hormone receptor-positive breast cancer and obesity. The investigators aim to understand whether participants are willing and able to take this medication once weekly for 6 months and whether it may help improve weight and overall health.
- Obesity / overweight
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Testing whether eloralintide helps people with obesity or overweight and type 2 diabetes lose weight
📍 Birmingham Clinical Research · Birmingham, AL · +39 more US sites · Get directions →
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.
- Kidney disease
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
Testing etelcalcetide in children with kidney disease on dialysis
📍 Childrens Hospital of Los Angeles · Los Angeles, CA · +9 more US sites · Get directions →
This is a phase 3 trial of etelcalcetide in pediatric participants with secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) on hemodialysis.
- Dementia / Alzheimer's
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
Studying whether ovarian hormones are linked to aging and Alzheimer’s risk in women
📍 Mayo Clinic · Jacksonville, FL · +1 more US site · Get directions →
The researchers are trying to determine whether ovarian hormones are associated with aging processes and with the risk of developing Alzheimer's disease in women.
- Type 2 diabetesKidney disease💵 May compensate
Mechanism of SGLT2 Inhibition in the Kidney
Testing how SGLT2 medicines affect kidney function in type 2 diabetes
📍 University of Michigan · Ann Arbor, MI · Get directions →
The goal of this open-label, non-randomized clinical trial is to determine what effects, if any, an FDA-approved drug class known as SGLT2 inhibitors (Canagliflozin or INVOKANA) has any protective effects on kidney function in Type 2 diabetes. We are looking for participants 18-80 years of age, who have had a clinical diagnosis of Type 2 diabetes for ≥ 3 years.
- Kidney disease
Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial
Testing medicines before surgery to reduce bleeding in kidney patients
📍 London Health Sciences Centre · London, Ontario · Get directions →
The BRACKETS pilot study is a multicentre, prospective, randomized controlled trial of prophylactic preoperative tranexamic acid (TXA) versus placebo and, using a partial factorial design, of prophylactic preoperative desmopressin versus placebo.
- Dementia / Alzheimer's
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
Testing whether yearly donanemab helps people with dementia after a prior study
📍 Banner Alzheimer's Institute · Phoenix, AZ · +39 more US sites · Get directions →
The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.
- Obesity / overweight
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Testing a medicine called eloralintide in adults with obesity or overweight without type 2 diabetes
📍 MFA Clinical Research · Tuscaloosa, AL · +39 more US sites · Get directions →
The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase.
- Obesity / overweight
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
Testing tradipitant for nausea and vomiting from GLP-1 medicines in adults with obesity or
📍 Vanda Investigational Site · Los Angeles, CA · +9 more US sites · Get directions →
The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.
- Kidney disease
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Testing long-term safety and effectiveness of zigakibart in adults with IgA kidney disease
📍 Colorado Kidney Care Nephrology · Denver, CO · +6 more US sites · Get directions →
The purpose of this study is to determine if zigakibart is safe and effective for long-term use in patients with immunoglobulin A nephropathy (IgAN). This is an extension study for patients who have already completed an another zigakibart study.
- Obesity / overweight
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Testing adding tirzepatide to ixekizumab for plaque psoriasis and weight issues
📍 Medical Dermatology Specialists · Phoenix, AZ · +39 more US sites · Get directions →
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
- Obesity / overweightFatty liver disease (NASH/MASH)💵 May compensate
Fibrosis Lessens After Metabolic Surgery
Testing whether metabolic surgery can reduce liver scarring in obesity
📍 Banner Health Center · Phoenix, AZ · +3 more US sites · Get directions →
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease affecting about 80% of people with obesity, ranging from simple fat deposits in the liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH), cellular injury, advanced fibrosis, cirrhosis, or hepatocellular carcinoma.
- Dementia / Alzheimer's
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Testing a drug called trontinemab for early Alzheimer’s disease dementia
📍 Banner Alzheimer?s Institute · Phoenix, AZ · +32 more US sites · Get directions →
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).
- Dementia / Alzheimer's
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
Testing a treatment called KarXT plus KarX-EC for psychosis in people with Alzheimer's disease
📍 Gilbert Neurology Partners/CCT Research · Gilbert, AZ · +5 more US sites · Get directions →
The purpose of this study is to evaluate KarXT + KarX-EC as a treatment for psychosis associated with Alzheimer's disease.
- Obesity / overweight
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
Testing a weekly injection medicine for adults with obesity and knee arthritis pain
📍 Arizona Research Center, Inc. · Phoenix, AZ · +18 more US sites · Get directions →
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and knee osteoarthritis. There are 2 study treatments in this study taken as injections under the skin once a week.
- Heart / cardiovascular diseaseKidney disease💵 May compensate
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
Testing whether sotagliflozin can slow kidney damage in type 1 diabetes
📍 Stanford University Medical Center · Stanford, CA · +12 more US sites · Get directions →
Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of substances called ketone bodies) observed with SGLT2i therapy in T1D.
- Kidney disease
Bone in CKD Alkali Response (BICARb Pilot Trial)
Testing whether potassium citrate improves bone health in people with chronic kidney disease
📍 Albert Einstein College of Medicine · The Bronx, NY · +1 more US site · Get directions →
The goal of this clinical trial is to test whether potassium citrate improves skeletal health in adults and children with chronic kidney disease. The main questions it aims to answer are: * To evaluate effects of potassium citrate treatment on bone quality and strength.
- DepressionDementia / Alzheimer's
Aβ Dynamics in LLMD
Testing how treating depression may change brain markers linked to Alzheimer’s
📍 NYU Langone Health · New York, NY · +1 more US site · Get directions →
This study will examine the biological factors that may modulate the relationship between depression and the development of Alzheimer's disease (AD). Since the direction of causation between depression and the biological factors associated with AD is unknown, the only way to understand cause and associated risk is to treat the depressive symptoms and examine the effects on AD biomarkers.
- Obesity / overweight
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
Testing an injection treatment once a week for people with obesity to help maintain weight loss
📍 Pinnacle Research Group LLC · Anniston, AL · +12 more US sites · Get directions →
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week.
- Dementia / Alzheimer's
Epidemiology and Biomarker Study in Alzheimer's Disease
Studying how memory changes over time and blood test results in people with dementia
📍 Care Access - Houston · Houston, TX · Get directions →
Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.
- Obesity / overweightCrohn's / ulcerative colitis (IBD)
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Testing two medicines together to reduce ulcerative colitis symptoms and weight in adults with
📍 Digestive Health Specialists · Dothan, AL · +36 more US sites · Get directions →
The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight. Participation in this study will last up to 61 weeks, including 52 weeks of treatment.
- Obesity / overweightCrohn's / ulcerative colitis (IBD)
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Testing treatments for adults with Crohn’s disease and excess weight
📍 Digestive Health Specialists · Dothan, AL · +34 more US sites · Get directions →
The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 61 weeks.
- Sickle cell disease
Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease
Testing whether routine red blood cell transfusions in pregnancy reduce sickle cell flare-ups or
📍 Grady Health System · Atlanta, GA · Get directions →
The goal of this study is to determine if there is a positive effect of prophylactic red blood cell (RBC) transfusion of leukoreduced, ABO, Rh (D/Cc/Ee) and Kell matched blood compared to standard of care on the number of episodes of acute sickle cell disease (SCD) manifestations or pregnancy-related complications requiring acute health care encounters (acute care/ER/Hospital visits) or resulting in death over the entirety of pregnancy until 2 months post-partum in women with SCD. RBC transfusion is the only disease-modifying therapy for pregnant women with SCD, and it is considered a standard treatment option however, there exists no consensus on the role of transfusion therapy in preventing SCD-related pregnancy complications.
- Dementia / Alzheimer's
Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease
Testing whether a brain PET scan can predict worsening memory problems
📍 Endeavor Health Systems · Evanston, IL · Get directions →
CMK-0301 is a multi-site, randomized clinical trial to evaluate the safety and efficacy of \[F-18\]Flornaptitril-PET (F-18 FNT-PET) for the prediction of clinical progression of Mild Cognitive Impairment (MCI) with either Suspected Chronic Traumatic Encephalopathy (CTE) or Alzheimer's Disease (AD). The primary objectives of the study are to: (1) To determine the accuracy of F-18 FNT-PET in prediction of clinical decline and (2) To assess the safety and tolerability of F-18 FNT.
- Obesity / overweight
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Testing injections once a week to help adults with obesity and type 2 diabetes lose weight
📍 Univ of Alabama Birmingham · Birmingham, AL · +14 more US sites · Get directions →
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week.
- Sickle cell disease
Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
Testing a single pneumococcal vaccine dose in children with sickle cell disease
📍 Site # 8400006 · Atlanta, GA · +4 more US sites · Get directions →
The purpose of this study is to measure whether PCV21 vaccine (investigational pneumococcal vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20vPCV (licensed pneumococcal vaccine) when given as a single dose to children aged 2 to 17 years with sickle cell disease who had received or not a previous vaccination with pneumococcal conjugate or pneumococcal polysaccharide vaccine.
- Obesity / overweight
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Testing how well CagriSema and cagrilintide help children with obesity lose weight
📍 Neighborhood Healthcare · Escondido, CA · +33 more US sites · Get directions →
This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study.
- Dementia / Alzheimer's
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Testing a treatment (KarXT plus KarX-EC) for memory problems in Alzheimer’s dementia
📍 Fullerton Neurology and Headache Center · Fullerton, CA · +29 more US sites · Get directions →
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
- Kidney disease
SAfety of Regional Citrate Anticoagulation (SARCA Study)
Testing the safety of regional citrate blood-thinner use in adults
📍 John L. McClellan Memorial Veterans' Hospital · Little Rock, AR · +9 more US sites · Get directions →
This is an Open-label, Prospective, Multicenter Study to Assess the SAfety of Regional Citrate Anticoagulation Delivered by the multiFiltratePRO system in Adult Patients Requiring Continuous Renal Replacement Therapy (SARCA Study).
- Obesity / overweight
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
Testing a once-weekly under-the-skin injection for weight loss in adults with obesity or overweight
📍 Kailera Clinical Site · Anniston, AL · +22 more US sites · Get directions →
The primary objective of the study is to determine the effects of KAI-9531 subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
- Kidney disease
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Testing a treatment for adults with chronic kidney disease to help slow progression
📍 Apogee Clinical Research · Huntsville, AL · +39 more US sites · Get directions →
This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study.
- Dementia / Alzheimer's
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
Comparing tau brain scan images in different types of dementia
📍 Perelman Center for Advance Medicine · Philadelphia, PA · Get directions →
The investigators will compare \[18F\]-PI-2620 tau PET scans from patients with frontotemporal lobar degeneration (FTLD), patients with non-amnestic presentations of Alzheimer's disease (naAD), and demographically matched cognitively normal subjects.
- Dementia / Alzheimer's
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
Testing a drug combination to treat agitation in adults with Alzheimer’s
📍 Chandler Clinical Trials, LLC · Chandler, AZ · +39 more US sites · Get directions →
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.
- Kidney disease
Patient-driven Management of BP in CKD
Testing whether pharmacist-guided blood pressure management helps CKD patients lower blood pressure
📍 Iowa City VA Health Care System, Iowa City, IA · Iowa City, IA · Get directions →
The proposed research will evaluate if patients managing their blood pressure medications under the guidance of a clinical pharmacist works better to lower blood pressure than patients monitoring their blood pressure at home and the standard care. 60 Veterans with chronic kidney disease (CKD) will be included in the study.
- Obesity / overweight
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
Testing tirzepatide with healthy diet and exercise for teens with obesity
📍 Children's Hospital Los Angeles · Los Angeles, CA · +13 more US sites · Get directions →
The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits.
- Showing the first 60 of 138. Add filters or a location to narrow down.